EE282 Budget Impact Analysis of Ivosidenib in Combination With Azacitidine for the Treatment of Previously Untreated mIDH1 Positive Acute Myeloid Leukaemia (AML) Patients, Ineligible for Intensive Induction Chemotherapy in Greece
Abstract
Authors
M Koulentaki S Ravanidis K Vellopoulou F Karathanou V Chotzagiannoglou A Beletsi G Kourlaba